Celularity has filed a patent for a method of isolating and characterizing exosomes derived from a cultivated placenta or a portion thereof. The method involves contacting the placenta with different mediums to obtain fractions of exosomes, which can then be isolated using centrifugation and affinity chromatography. The exosomes can be used as biotechnological tools and therapeutics for the treatment of subjects. GlobalData’s report on Celularity gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Celularity, Cytokine activate T-cell based compositions was a key innovation area identified from patents. Celularity's grant share as of September 2023 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
Method of isolating exosomes from placenta or portion thereof
A recently filed patent (Publication Number: US20230310319A1) describes a method for isolating exosomes from a placenta or a portion thereof. Exosomes are small vesicles that play a role in cell-to-cell communication and have potential therapeutic applications. The method involves contacting the placenta with different mediums to obtain fractions containing exosomes. These fractions can then be isolated using techniques such as centrifugation and affinity chromatography. The patent also mentions the inclusion of amniotic membrane in the placenta and specifies that the method is applicable to human placenta.
The patent further describes a composition comprising exosomes derived from human placenta. These exosomes are said to be positive for various markers, including CD1c, CD20, CD24, CD25, CD29, CD2, CD3, CD8, CD9, CD11c, CD14, CD19, CD31, CD40, CD41b, CD42a, CD44, CD45, CD49e, CD4, CD56, CD62P, CD63, CD69, CD81, CD86, CD105, CD133-1, CD142, CD146, CD209, CD326, HLA-ABC, HLA-DRDPDQ, MCSP, ROR1, SSEA-4, or combinations thereof. The composition also includes exosomes that contain non-coding RNA molecules, particularly microRNAs. Specific microRNAs mentioned in the patent include hsa-mir-26b, hsa-miR-26b-5p, hsa-mir-26a-2, hsa-mir-26a-1, hsa-miR-26a-5p, hsa-mir-30d, hsa-miR-30d-5p, hsa-mir-100, hsa-miR-100-5p, hsa-mir-21, hsa-miR-21-5p, hsa-mir-22, hsa-miR-22-3p, hsa-mir-99b, hsa-miR-99b-5p, hsa-mir-181a-2, hsa-mir-181a-1, hsa-miR-181a-5p, and combinations thereof.
The patent also suggests potential applications of the composition. It states that the exosomes derived from human placenta can be used for angiogenesis or vascularization in a subject. The method involves administering the composition to the subject, with the patent specifically mentioning that the subject can be human.
In summary, the filed patent describes a method for isolating exosomes from placenta and a composition comprising exosomes derived from human placenta. The method involves contacting the placenta with different mediums and isolating the exosomes using various techniques. The composition includes exosomes that are positive for specific markers and contain non-coding RNA molecules, particularly microRNAs. The patent suggests that the composition can be used for angiogenesis or vascularization in a subject, with the subject being human.